Display options
Cite
van Gool MH, Aukema TS, Sinaasappel M, et al. Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib. J Thorac Dis. 2016;8(3):E200-3doi: 10.21037/jtd.2016.02.10.
van Gool, M. H., Aukema, T. S., Sinaasappel, M., Valdés Olmos, R. A., & Klomp, H. M. (2016). Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib. Journal of thoracic disease, 8(3), E200-3. https://doi.org/10.21037/jtd.2016.02.10
van Gool, Matthijs H, et al. "Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib." Journal of thoracic disease vol. 8,3 (2016): E200-3. doi: https://doi.org/10.21037/jtd.2016.02.10
van Gool MH, Aukema TS, Sinaasappel M, Valdés Olmos RA, Klomp HM. Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib. J Thorac Dis. 2016 Mar;8(3):E200-3. doi: 10.21037/jtd.2016.02.10. PMID: 27076970; PMCID: PMC4805797.
Copy Download .nbib Format: NLM
Share it on

J Thorac Dis. 2016 Mar;8(3):E200-3. doi: 10.21037/jtd.2016.02.10.

Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib.

Journal of thoracic disease

Matthijs H van Gool, Tjeerd S Aukema, Michiel Sinaasappel, Renato A Valdés Olmos, Houke M Klomp

Affiliations

  1. 1 Department of Surgical Oncology, 2 Department of Nuclear Medicine, 3 Department of Physics, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

PMID: 27076970 PMCID: PMC4805797 DOI: 10.21037/jtd.2016.02.10

Abstract

Response monitoring using fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography (FDG-PET/CT) textural features has potential in targeted treatment with erlotinib in non-small cell lung cancer (NSCLC) patients. Patients with substantial decrease of metabolic activity during erlotinib treatment will probably benefit from continued treatment. However, various aspects of the method (quantification tools, cut-off values, etc.) need to be standardized before the software becomes widely available in a similar manner as standardized uptake value (SUV) measurements. Heterogeneity on FDG-PET/CT opened an additional window for innovation but simultaneously a new challenge for molecular hybrid imaging.

Keywords: Fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography (FDG-PET/CT); epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI); non-small cell lung cancer (NSCLC)

References

  1. Chest. 2000 Mar;117(3):773-8 - PubMed
  2. Lung Cancer. 2012 May;76(2):235-41 - PubMed
  3. Cochrane Database Syst Rev. 2014 Nov 13;(11):CD009519 - PubMed
  4. Lancet Oncol. 2012 Mar;13(3):239-46 - PubMed
  5. Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):204-11 - PubMed
  6. Lung Cancer. 2011 Apr;72(1):3-8 - PubMed
  7. J Nucl Med. 2014 Jul;55(7):1081-6 - PubMed
  8. Clin Cancer Res. 2010 Jun 15;16(12):3163-70 - PubMed
  9. Science. 2004 Jun 4;304(5676):1497-500 - PubMed
  10. Cancer Treat Rev. 2012 Aug;38(5):416-30 - PubMed
  11. Radiology. 2015 Sep;276(3):883-93 - PubMed
  12. J Nucl Med. 2005 Jul;46(7):1144-50 - PubMed
  13. J Clin Oncol. 2009 Apr 10;27(11):1906-14 - PubMed
  14. J Clin Oncol. 2009 Aug 10;27(23):3868-74 - PubMed
  15. World J Radiol. 2014 Jul 28;6(7):392-8 - PubMed
  16. J Clin Oncol. 2015 Oct 20;33(30):3488-515 - PubMed
  17. J Nucl Med. 2012 May;53(5):693-700 - PubMed
  18. J Clin Oncol. 2012 Aug 1;30(22):2731-8 - PubMed
  19. AJR Am J Roentgenol. 2011 May;196 (5):1176-81 - PubMed
  20. Clin Nucl Med. 2012 Nov;37(11):1058-64 - PubMed

Publication Types